On May 7, 2026, Hims & Hers (NYSE: HIMS) launched Labs AI, an embedded artificial intelligence agent that reads a customer's bloodwork and explains it in plain language. The product covers 130 biomarker tests across 10 health categories, including heart health, metabolism, hormones, inflammation, and stress. It is positioned as an educational tool, not a diagnostic one, and it hands off to a licensed provider when a clinical conversation is warranted.[1]
Labs AI is the first in what the company has said will be a series of AI care agents. The Chief Medical Officer (CMO) Patrick Carroll, MD, has explicitly named glucagon-like peptide-1 receptor agonist drugs (GLP-1 drugs, including Ozempic and Wegovy) for weight management as the next vertical, and the Chief Technology Officer (CTO) Mo Elshenawy (who joined from Cruise, the self-driving car company) has described the broader project as an "AI-native" care platform.[1] Labs AI is therefore a deliberate move toward a longitudinal cash-pay consumer health relationship, the same model concierge medicine sells, rather than a one-off feature.
The headline question for patients is whether this changes the calculus of paying for concierge medicine or direct primary care (DPC). The short answer is that it changes the floor of what those models need to deliver, but it does not replace them for the patients they were built for. This piece walks through what Labs AI does, what it does not do, and where it leaves the concierge value proposition.
What Labs AI Actually Does
The product fits inside the existing Hims & Hers Labs subscription, which launched in November 2025 as a $9.99-per-month direct-to-consumer biomarker testing program.[1] A customer pays the subscription, submits a sample through the Labs program (and, after the company's recent YourBio Health acquisition, increasingly through at-home capillary blood draws), and receives results back inside the app. Labs AI sits on top of those results.[2]
A few specifics worth knowing:
Spec | Detail |
|---|---|
Coverage | 130 biomarker tests across 10 health areas |
Stated scope | Educational, "not set up to diagnose," recommends a licensed provider when warranted |
Architecture | Retrieval-augmented reasoning grounded in a proprietary clinical knowledge base, with structured access to the customer's current and historical biomarkers |
Safety layer | Clinician-authored rubrics encoded as automated tests, layered evaluation gating every code change, adversarial prompt-injection sweeps |
Provider integration | When the AI recommends a clinical handoff, the licensed provider receives the Labs AI summary so context is preserved |
Data discipline | Does not pull from the open internet; customer data kept internal per the company |
The thing that separates Labs AI from a consumer chatbot like ChatGPT is the licensed provider group in the loop. When the AI suggests a clinical conversation, a real Hims & Hers provider sees the same summary the customer saw, which closes part of the gap between AI tooling and a physician interaction. The product still falls short of a full physician relationship; it is closer to a triage AI sitting in front of a transactional telehealth provider group, with the customer's lab history threaded through.
Why This Matters for Concierge Medicine
The standard concierge marketing pitch leans on three patient frustrations:
You cannot reach your doctor.
You cannot get your labs explained.
You cannot get medication and tests ordered without insurance friction.
Labs AI directly substitutes for the second of those at near-zero marginal cost for an existing Hims & Hers customer. A patient who already pays $9.99 per month for the Labs subscription can now get personalized lab interpretation tied to a real provider, rather than scheduling a 15-minute appointment with a primary care doctor who may or may not have time to walk through the numbers.[3]
That is a real product step, and it is the first time a direct-to-consumer telehealth company has shipped a tool that competes head-on with one of concierge medicine's three core selling points. The fair read on Labs AI is that it is a moderate competitive event for concierge, not a five-alarm one. The structural reasons it is moderate:
Labs AI is single-feature, not relationship. Concierge sells longitudinal context across years, in-person physical examination, ordering of confirmatory imaging and specialist referrals, and after-hours escalation when something goes wrong. Labs AI explains a bloodwork panel. The two products do not occupy the same row in a feature table once the patient's care gets complex.
The acuity gap is large. The patients who pay $3,000 to over $40,000 per year for concierge medicine are typically managing multiple chronic conditions, complex medication lists, post-surgical recovery, or longevity workups that involve imaging and specialist coordination. The patients using Labs AI are paying $9.99 per month and reading their cholesterol numbers. Both populations have real medical needs, but they are not the same medical needs.
Provider-grounded is not provider-equivalent. Labs AI's edge over a generic chatbot is the licensed provider group standing behind it. That is a meaningful improvement on the user experience of the consumer chatbot pattern, but the Hims & Hers provider relationship is asynchronous and transactional. That setup differs from a physician who has known the patient across years, has done the physical exam, and will pick up the phone at 9 p.m. on a Sunday.
The Price-Floor Effect Is the Actual Concern
The deeper consequence of Labs AI is what happens to the value floor of concierge and direct primary care (DPC) content marketing, not direct substitution.
For the last decade, "your doctor explains your labs" has been a routine line in concierge sales materials. Labs AI does not eliminate that line, but it makes it less differentiating. Once a $9.99-per-month consumer can get a written, personalized lab interpretation with a real provider attached, the concierge value proposition on labs review has to compete on depth, time, longitudinal context, or coverage of the rest of the care experience. The pitch shifts from "we explain your labs" to "we explain your labs in the context of a physical exam you sat through, a five-year medication history we know cold, and a relationship that means we know what is normal for you specifically."
That is a sharper pitch, and it is honest to the patients who actually benefit from concierge care. It is also a harder pitch to write, because it leans on the relationship rather than the deliverable.
Where Labs AI Is Enough, and Where It Is Not
A rough way to think about which patients are well served by each product:
Patient profile | Labs AI is probably enough | A concierge or DPC physician is the better fit |
|---|---|---|
Healthy adult, no chronic conditions, single annual lab panel, fluent in their own care | ✅ | |
Adult with one or two stable chronic conditions on a steady medication list | ✅ for routine labs | When something changes |
Adult on a GLP-1 medication, multiple medications, or a complex metabolic workup | ✅ | |
Patient with three or more medications, a recent hospitalization, or a new diagnosis | ✅ | |
Patient who wants longevity-oriented care, advanced imaging, and a coordinated specialist network | ✅ | |
Patient with a child with a chronic condition (asthma, allergies, ADHD) | ✅ | |
Patient who values 24/7 access to a named physician they actually know | ✅ |
The honest framing is that Labs AI is a real product for the routine case and an inadequate one for the complex case. The patients who already get the most from concierge medicine, the people described in the NextMD guide to concierge medicine for chronic conditions, still need the in-person physical, the longitudinal record, and the physician who picks up the phone.
For a closer look at what the day-to-day inside a concierge practice actually feels like, see how concierge medicine actually works behind the scenes. And for the research evidence on why this model produces lower emergency room use across the population, see why concierge medicine patients visit the ER 40% less often.
What the Concierge Tiers Look Like
NextMD groups concierge practices into three pricing tiers. Some named examples to anchor the spread:
Entry-level concierge ($2,500 to $5,000 per year). Practices like The Cove Concierge Medicine and James Wallstrom, MD. These practices deliver same-week visits, a direct physician line, and the time to actually walk through a year of labs.
Premium concierge ($5,000 to $12,000 per year). Practices like WVL Synergy in Naples, Florida. Many premium-tier practices add in-house phlebotomy, body composition scanning, and a longer initial intake.
Ultra-premium concierge ($15,000 and up, commonly over $40,000 per year). Practices like MD2 and Private Medical. At this tier, the practice handles the entire metabolic and longevity workup, including imaging, specialist coordination, and travel-ready medical support.
Direct primary care covers the lower end. DPC memberships at $50 to $200 per month buy the same panel-size dynamic as concierge without the higher per-year fee.
For local listings, browse concierge doctors in Naples, FL or search nationally at nextmd.ai/search.
The Next Signal: GLP-1 AI Care Coach
The CTO has said the next AI care agent vertical is GLP-1 weight management, and Hims & Hers has been adding to its weight-management infrastructure quickly. In the first quarter of 2026 alone, the company signed direct distribution deals for Wegovy with Novo Nordisk and Zepbound with Eli Lilly, fulfilled 125,000 Wegovy shipments inside six weeks, and announced plans for an "AI weight loss companion."[2] If that ships in late 2026, it would be the second concierge-adjacent feature substitution event in a year.
That matters because the GLP-1 maintenance problem (long-term labs, dose adjustments, side effects, off-ramp planning) is one of the strongest reasons a patient currently picks concierge or DPC over a starter telehealth platform. For the patients in that population, the right move is to read the NextMD guide to long-term GLP-1 care and pick a doctor for year two rather than waiting for an AI coach that may or may not arrive on the announced timeline.
What It Means for the Concierge Industry
For practices, the message is that the lab-interpretation pitch is not going away, but it is no longer a differentiator on its own. The differentiator is the relationship: the physical exam, the longitudinal record, the after-hours phone access, the coordination of specialists. Content marketing, intake conversations, and pricing pages should lead with the relationship pitch and treat lab interpretation as one outcome of the relationship, not as the headline.
For patients, the message is that the choice between Labs AI and concierge medicine comes down to what you need over the course of a year, not what you need for a single lab interpretation: routine education on a few biomarkers, or an ongoing relationship with a physician who knows your full medical picture.
A Note From the Author
I am not a doctor. Nothing in this article should be considered medical advice. This piece is intended as a plain-language explanation of a recent product launch and how it fits into the broader concierge and direct primary care landscape. Before making any change to your medical care, talk to a licensed physician who knows your medical history.
NextMD helps you find and compare concierge medicine and direct primary care practices across the United States. Browse practices by city, compare pricing, and find a doctor who has time for you at nextmd.ai/search.
Sources
Landi, H. (2026, May 7). Hims & Hers debuts AI agent to help users interpret lab results. Fierce Healthcare. Read on Fierce Healthcare
Landi, H. (2026, May 12). Hims & Hers swings to a loss in Q1 amid shift in GLP-1 strategy. Fierce Healthcare. Read on Fierce Healthcare
Neprash, H.T., Everhart, A., McAlpine, D., Smith, L.B., Sheridan, B., & Cross, D.A. (2023). Measuring Primary Care Exam Length Using Electronic Health Record Data. Medical Care, 61(7), 414-422. Read on PubMed (PMID 33301282). Referenced for the average primary care visit length.
Busch, F., Grzeskowiak, D., & Huth, E. (2020). Direct Primary Care: Evaluating a New Model of Delivery and Financing. Society of Actuaries / Milliman. Read the full report on SOA.org. Referenced for the 40.51% emergency room reduction in DPC patients.